Skip to main content
. 2024 Oct 2;25(19):10617. doi: 10.3390/ijms251910617

Figure 5.

Figure 5

Isoprenaline- and forskolin-mediated contractile responses. (a) Cumulative concentration–response curve. (b) Emax, Efficacy. C, Control (n = 8); D, Diabetic (n = 7); SV, Sacubitril/valsartan-treated diabetic (n = 8); and V, Valsartan-treated diabetic (n = 6). *, p < 0.05 compared to control. (c) Contraction response at 3 µM forskolin (% of control). C, Control (n = 7); D, Diabetic (n = 7); SV, Sacubitril/valsartan-treated diabetic (n = 5); and V, Valsartan-treated diabetic (n = 5).